

Personalized medicine research strikes early for heart genes

A landmark paper identifying genetic signatures that predict which patients will respond to a life-saving drug for treating congestive [heart failure](#) has been published by a research team co-led by Stephen B. Liggett, MD, of the University of South Florida. The study, drawing upon a randomized placebo-controlled trial for the [beta blocker](#) bucindolol, appears this month in the online international journal *PLoS ONE*. In addition to Dr. Liggett, whose laboratory discovered and characterized the two genetic variations, Christopher O'Connor, MD, of Duke University Medical Center, and Michael Bristow, MD, PhD, of ARCA biopharma and the University of Colorado Anschutz Medical Campus, were leading members of the research team.

View the original article here: [Personalized medicine research strikes early for heart genes – News-Medical.net](#)